Simmons Hanly Conroy Investigates Talcum Powder Link to Ovarian Cancer

New Data Shows Risk of Ovarian Cancer Higher Among Women Who Regularly Use Baby Powder Products Containing Talcum Powder

Mar 14, 2016, 13:02 ET from Simmons Hanly Conroy

ALTON, Ill., March 14, 2016 /PRNewswire/ -- Simmons Hanly Conroy, one of the nation's largest mass tort law firms, has launched an investigation into claims that products containing talcum powder may increase the risk of ovarian cancer in women who regularly use the products.

Logo - http://photos.prnewswire.com/prnh/20160314/343713LOGO 

Talcum powder is widely used in cosmetics such as baby powder because of its ability to absorb moisture, eliminate friction and prevent rashes. Largely manufactured by Johnson & Johnson (J&J), products containing talcum powder have become a symbol of freshness and cleanliness for women. However, if used for feminine hygiene, doctors have suggested talcum powder can reach the ovaries and ultimately cause cancer. 

A new study conducted by Brigham and Women's Hospital in Boston, and published in the journal Epidemiology, outlines the link between talcum powder and ovarian cancer, namely when the powder has been applied to the genital region. In a study comparing talcum powder use among women with ovarian cancer and women without illness, doctors found that applying the product to genitals, underwear and sanitary napkins increased the risk of developing ovarian cancer by one third.

"This is a very serious and sensitive issue for women," said Jayne Conroy, shareholder and pharmaceutical attorney at Simmons Hanly Conroy. "A number of women who used baby powder, body powder or other deodorizing talcum powder were unaware they were putting themselves in danger."

J&J continues to deny talcum powder links to ovarian cancer and does not use warning labels on its products.

Learn more about the firm's ongoing talcum powder investigation.

About Simmons Hanly Conroy, LLC

Simmons Hanly Conroy is one of the nation's largest mass tort law firms and has recovered more than $5 billion in verdicts and settlements for plaintiffs. Primary areas of litigation include asbestos and mesothelioma, pharmaceutical, consumer protection, environmental and personal injury. The firm's attorneys have been appointed to leadership in numerous national multidistrict litigations, including Vioxx, Yaz and Toyota Unintended Acceleration. Offices are located in New York City, Chicago, San Francisco, Los Angeles, St. Louis, and Alton, Ill. Read more at www.simmonspharmalaw.com.

Contact: Mark Motley, Chief Marketing Officer
618.259.2222 |  mmotley@simmonsfirm.com  

SOURCE Simmons Hanly Conroy



RELATED LINKS

http://www.simmonspharmalaw.com